Price
Target price
€4.07
€4.07
2.790%
0.11
2.790%
-
05.12.23 / Tradegate
WKN: A14QXP / Name: Ose Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ose Pharma International S.A. Stock
Ose Pharma International S.A. gained 2.790% today.
For the coming years our community has positive and negative things to say abot the Ose Pharma International S.A. stock. Criterium "EBIT growth" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Ose Pharma International S.A. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
News
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1